Literature DB >> 20530702

Biobehavioral, immune, and health benefits following recurrence for psychological intervention participants.

Barbara L Andersen1, Lisa M Thornton, Charles L Shapiro, William B Farrar, Bethany L Mundy, Hae-Chung Yang, William E Carson.   

Abstract

PURPOSE: A clinical trial was designed to test the hypothesis that a psychological intervention could reduce the risk of cancer recurrence. Newly diagnosed regional breast cancer patients (n = 227) were randomized to the intervention-with-assessment or the assessment-only arm. The intervention had positive psychological, social, immune, and health benefits, and after a median of 11 years the intervention arm was found to have reduced the risk of recurrence (hazard ratio, 0.55; P = 0.034). In follow-up, we hypothesized that the intervention arm might also show longer survival after recurrence. If observed, we then would examine potential biobehavioral mechanisms. EXPERIMENTAL
DESIGN: All patients were followed; 62 recurred. Survival analyses included all 62. Upon recurrence diagnosis, those available for further biobehavioral study were accrued (n = 41, 23 intervention and 18 assessment). For those 41, psychological, social, adherence, health, and immune (natural killer cell cytotoxicity, T-cell proliferation) data were collected at recurrence diagnosis and 4, 8, and 12 months later.
RESULTS: Intent-to-treat analysis revealed reduced risk of death following recurrence for the intervention arm (hazard ratio, 0.41; P = 0.014). Mixed-effects follow-up analyses with biobehavioral data showed that all patients responded with significant psychological distress at recurrence diagnosis, but thereafter only the intervention arm improved (P values < 0.023). Immune indices were significantly higher for the intervention arm at 12 months (P values < 0.017).
CONCLUSIONS: Hazards analyses augment previous findings in showing improved survival for the intervention arm after recurrence. Follow-up analyses showing biobehavioral advantages for the intervention arm contribute to our understanding of how improved survival was achieved. (c) 2010 AACR.

Entities:  

Mesh:

Year:  2010        PMID: 20530702      PMCID: PMC2910547          DOI: 10.1158/1078-0432.CCR-10-0278

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  38 in total

Review 1.  Biobehavioral outcomes following psychological interventions for cancer patients.

Authors:  Barbara L Andersen
Journal:  J Consult Clin Psychol       Date:  2002-06

Review 2.  Dose intensity for breast cancer.

Authors:  D K Armstrong; N E Davidson
Journal:  Oncology (Williston Park)       Date:  2001-06       Impact factor: 2.990

3.  Prognostic significance of natural killer cell activity in patients with gastric carcinoma: a multivariate analysis.

Authors:  H Takeuchi; Y Maehara; E Tokunaga; T Koga; Y Kakeji; K Sugimachi
Journal:  Am J Gastroenterol       Date:  2001-02       Impact factor: 10.864

4.  The effect of group psychosocial support on survival in metastatic breast cancer.

Authors:  P J Goodwin; M Leszcz; M Ennis; J Koopmans; L Vincent; H Guther; E Drysdale; M Hundleby; H M Chochinov; M Navarro; M Speca; J Hunter
Journal:  N Engl J Med       Date:  2001-12-13       Impact factor: 91.245

5.  Cellular immunologic parameters related to age, gender, and stage in lung cancer patients.

Authors:  H Nakamura; N Kawasaki; M Hagiwara; M Saito; C Konaka; H Kato
Journal:  Lung Cancer       Date:  2000-05       Impact factor: 5.705

6.  Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials.

Authors:  Chantal Quinten; Corneel Coens; Murielle Mauer; Sylvie Comte; Mirjam A G Sprangers; Charles Cleeland; David Osoba; Kristin Bjordal; Andrew Bottomley
Journal:  Lancet Oncol       Date:  2009-08-18       Impact factor: 41.316

7.  Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A.

Authors:  Maria Liljefors; Bo Nilsson; Anna-Lena Hjelm Skog; Peter Ragnhammar; Håkan Mellstedt; Jan-Erik Frödin
Journal:  Int J Cancer       Date:  2003-07-10       Impact factor: 7.396

8.  Cognitive-existential group psychotherapy for women with primary breast cancer: a randomised controlled trial.

Authors:  David W Kissane; Sidney Bloch; Graeme C Smith; Patricia Miach; David M Clarke; Jillian Ikin; Anthony Love; Nadia Ranieri; Dean McKenzie
Journal:  Psychooncology       Date:  2003-09       Impact factor: 3.894

9.  Cellular immunity in breast cancer patients completing taxane treatment.

Authors:  William E Carson; Charles L Shapiro; Timothy R Crespin; Lisa M Thornton; Barbara L Andersen
Journal:  Clin Cancer Res       Date:  2004-05-15       Impact factor: 12.531

Review 10.  Survival analysis part IV: further concepts and methods in survival analysis.

Authors:  T G Clark; M J Bradburn; S B Love; D G Altman
Journal:  Br J Cancer       Date:  2003-09-01       Impact factor: 7.640

View more
  63 in total

Review 1.  Neuroendocrine influences on cancer progression.

Authors:  Guillermo N Armaiz-Pena; Steve W Cole; Susan K Lutgendorf; Anil K Sood
Journal:  Brain Behav Immun       Date:  2012-06-21       Impact factor: 7.217

2.  Dissemination of an evidence-based treatment for cancer patients: training is the necessary first step.

Authors:  Brittany M Brothers; Kristen M Carpenter; Rebecca A Shelby; Lisa M Thornton; Georita M Frierson; Kyle L Patterson; Barbara L Andersen
Journal:  Transl Behav Med       Date:  2015-03       Impact factor: 3.046

3.  Emotions and social relationships for breast and gynecologic patients: a qualitative study of coping with recurrence.

Authors:  Lisa M Thornton; Anna O Levin; Caroline S Dorfman; Neha Godiwala; Carolyn Heitzmann; Barbara L Andersen
Journal:  Psychooncology       Date:  2013-10-14       Impact factor: 3.894

4.  Fine-tuning the truth.

Authors:  Elisabeth E Elder; Raimund Jakesz
Journal:  World J Surg       Date:  2011-10       Impact factor: 3.352

5.  Lemons to lemonade: Effects of a biobehavioral intervention for cancer patients on later life changes.

Authors:  Claire C Conley; Barbara L Andersen
Journal:  Health Psychol       Date:  2019-03       Impact factor: 4.267

Review 6.  The impact of psychosocial stress and stress management on immune responses in patients with cancer.

Authors:  Michael H Antoni; Firdaus S Dhabhar
Journal:  Cancer       Date:  2019-02-15       Impact factor: 6.860

7.  Trajectories of Stress, Depressive Symptoms, and Immunity in Cancer Survivors: Diagnosis to 5 Years.

Authors:  Barbara L Andersen; Neha Godiwala Goyal; Travis D Westbrook; Brenden Bishop; William E Carson
Journal:  Clin Cancer Res       Date:  2016-07-12       Impact factor: 12.531

Review 8.  Psychosocial intervention effects on adaptation, disease course and biobehavioral processes in cancer.

Authors:  Michael H Antoni
Journal:  Brain Behav Immun       Date:  2012-05-22       Impact factor: 7.217

9.  A randomized trial comparing live and telemedicine deliveries of an imagery-based behavioral intervention for breast cancer survivors: reducing symptoms and barriers to care.

Authors:  Lyn W Freeman; Rebecca White; Chelsea G Ratcliff; Sue Sutton; Mary Stewart; J Lynn Palmer; Judith Link; Lorenzo Cohen
Journal:  Psychooncology       Date:  2014-08-22       Impact factor: 3.894

10.  Hope and benefit finding: Results from the PRISM randomized controlled trial.

Authors:  Abby R Rosenberg; Miranda C Bradford; Krysta S Barton; Nicole Etsekson; Elizabeth McCauley; J Randall Curtis; Joanne Wolfe; K Scott Baker; Joyce P Yi-Frazier
Journal:  Pediatr Blood Cancer       Date:  2018-09-30       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.